Results 211 to 220 of about 145,099 (296)
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies. [PDF]
Martino EA +10 more
europepmc +1 more source
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta +13 more
wiley +1 more source
Low serum IgE is associated with an increased risk of chronic lymphocytic leukemia: a large retrospective cohort study. [PDF]
Cohen R +10 more
europepmc +1 more source
Bone Marrow Pathology in Cold Agglutinin‐Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases
ABSTRACT Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia (AIHA). CAD occurs in the context of a small clonal B‐cell lymphoproliferation restricted to blood and/or bone marrow (BM), without overt or extramedullary lymphoma. The WHO‐HAEM5 introduced a description of the CAD‐associated lymphoproliferative disorder (CAD‐LPD) in ...
Anne‐Marie L. Becking +6 more
wiley +1 more source
Comparative evaluation of two NGS-based assays for somatic hypermutation analysis of IGHV genes in chronic lymphocytic leukemia. [PDF]
Kang Y +5 more
europepmc +1 more source
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive hematological malignancy with a poor prognosis and limited therapeutic options. ATL cells exhibit aberrant surface glycosylation patterns resulting from dysregulated glycosyltransferase expression, representing a potentially tumor‐specific therapeutic target.
Yuichiro Uchida +7 more
wiley +1 more source
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino +13 more
wiley +1 more source
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia. [PDF]
Benrashid S, Woyach JA.
europepmc +1 more source

